• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Blue Earth Diagnostics, Siemens Healthineers Partner to Advance Prostate Cancer Imaging with AI

by Fred Pennic 05/08/2024 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know: 

– Blue Earth Diagnostics, a Bracco company and leader in innovative PET radiopharmaceuticals, announced a data-sharing agreement with Siemens Healthineers. 

– This collaboration focuses on anonymized data from Blue Earth’s Phase 3 LIGHTHOUSE trial of POSLUMA® (flotufolastat F 18) injection, used for imaging prostate cancer.

Optimizing AI for Improved Prostate Cancer Detection

Siemens Healthineers will leverage the anonymized clinical data and images from the LIGHTHOUSE trial to enhance its AI-powered analytics for prostate cancer. This will lead to:

  • More Precise Image Quantification: AI algorithms will be refined to provide more accurate measurement of prostate cancer lesions detected by POSLUMA PET scans.
  • Enhanced Image Interpretation: Advanced AI tools will be developed to assist healthcare professionals in interpreting PET scans, potentially leading to earlier and more precise diagnoses.

About POSLUMA®

POSLUMA, previously known as 18F-rhPSMA-7.3, is a recently approved radiopharmaceutical for PET imaging of prostate cancer. It targets the Prostate-Specific Membrane Antigen (PSMA), a protein often overexpressed by prostate cancer cells. This targeted approach allows for more effective detection of prostate cancer compared to traditional imaging methods.

Details of the LIGHTHOUSE Trial

The LIGHTHOUSE trial was a large-scale clinical study involving over 350 men with newly diagnosed prostate cancer. It evaluated the safety and effectiveness of POSLUMA PET imaging in identifying prostate cancer lesions.

Blue Earth Diagnostics: A Leader in rhPSMA Technology

Blue Earth Diagnostics holds exclusive worldwide rights to the radiohybrid Prostate-Specific Membrane Antigen (rhPSMA) diagnostic imaging technology. This technology has the potential to revolutionize prostate cancer diagnosis and treatment.

“Blue Earth Diagnostics is committed to helping men with prostate cancer across the care continuum, and we recognize the importance of AI in advancing healthcare,” said David Gauden, D.Phil., Chief Executive Officer, Blue Earth Diagnostics. “AI-based algorithms have the potential to streamline the PET/CT analytical workflow for hospitals and imaging centers by efficiently providing physicians with information critical to patient management and care. Blue Earth Diagnostics has a long-standing relationship with Siemens Healthineers, a leading medical technology company pioneering breakthroughs in healthcare.”
  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Artificial Intelligence

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

 Selecting the Right EMR: A Practical Guide to Streamlining Your Practice and Enhancing Patient Care

Selecting the Right EMR: A Practical Guide to Streamlining Your Practice and Enhancing Patient Care

Featured Interview

Virta Health CEO: GLP-1s Didn’t Kill Weight Watchers, Its Broken Model Did

Most-Read

Beyond the Hype: Building AI Systems in Healthcare Where Hallucinations Are Not an Option

Beyond the Hype: Building AI Systems in Healthcare Where Hallucinations Are Not an Option

Health IT Sector Navigates Policy Turbulence with Resilient M&A

Health IT’s New Chapter: IPOs Return, Resilient M&A, Valuations Rise in 1H 2025

PwC Report: US Medical Cost Trend to Remain Elevated at 8.5% in 2026

PwC Report: US Medical Cost Trend to Remain Elevated at 8.5% in 2026

Philips Launches ECG AI Marketplace, Partnering with Anumana to Enhance Cardiac Care with AI-Powered Diagnostics

Philips Launches ECG AI Marketplace, Partnering with Anumana to Enhance Cardiac Care with AI-Powered Diagnostics

WeightWatchers Emerges from Bankruptcy, Launches New Menopause Program

WeightWatchers Emerges from Bankruptcy, Launches New Menopause Program

CMS Finalizes New Interoperability and Prior Authorization Rule

CMS Proposes 2026 Physician Fee Schedule Rule: Boosting Primary Care, Cutting Waste, and Modernizing Payments

Beyond SaaS: How Agent as a Service is Transforming Healthcare Automation

Beyond SaaS: How Agent as a Service is Transforming Healthcare Automation

New Strategies Needed: No Surprises Act and the Challenges for Payors with Provider Data Inaccuracies

Samsung Acquires Xealth to Accelerate Connected Care Vision

Samsung Acquires Xealth to Accelerate Connected Care Vision

AI Dominates Digital Health Investment in First Half of 2025

Rock Health Report: AI Dominates Digital Health Investment in First Half of 2025

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |